Oncology

In 2017, lung cancer is projected to be the second most prevalent type of cancer in the United States, with about 222,500 new cases and is estimated to still be the leading cause of cancer-related death, with 155,870 deaths.

A new system allows researchers to test multiple drug combinations in cultured cancer stem cells from patients.

High oncology drug costs could impact adherence to cancer treatment.

Mastectomy for early-stage breast cancer increases the risk of missing more than 1 month of work.

Novel predictive model harnesses technology to diagnose ovarian cancer more accurately than ultrasound.

Glecaprevir and pibrentasvir (Mavyret) shows efficacy across hepatitis C genotypes.

Elvin Montanez, PharmD, chief operations officer at BioPlus Specialty Pharmacy, discusses how to improve patient outcomes and decrease oncology spend.

A look at last week's top stories in the world of pharmacy.

Combining cancer drugs may help prevent drug resistance.

A look at last week's top stories in the world of pharmacy.

Multiple mutations may work together to develop drug-resistant non-small cell lung cancer.

Direct-acting antivirals drugs show similar cure rates in co-infected patients as high as mono-infected patients.

A cancer diagnosis in young patients can cause post-traumatic stress disorder that can persist long afterwards.

Medicare sequester cuts could restrict access to care for seniors with cancer.

Doubling Medicare sequester cuts could reduce access to lower-cost cancer treatment.

Only 15% of patients with a 20% to 24% risk of breast cancer received a recommended MRI screening.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

Sunitinib malate (Sutent) is an adjuvant therapy for adults at risk of recurrent renal cell carcinoma following nephrectomy.

Fulvestrant (Faslodex) plus abemaciclib may improve progression-free survival among patients with advanced or metastatic breast cancer.

Exposure to ammonia found to amplify breast cancer cell proliferation.

Nine other countries are on track to eliminate the hepatitis C virus by 2030.

Top news of the week from Specialty Pharmacy Times.

Study finds association between warfarin use and cancer incidence to determine whether warfarin has anticancer potential.

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.

Brentuximab vedotin (Adcetris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.

Brentuximab vedotin (Adcetris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.

Ribociclib (Kisqali) combination therapy may improve survival among premenopausal breast cancer patients.

A comprehensive knowledge of the risk of breast cancer can lead to better screening.